Sonidegib was evaluated in a phase I–II study where the cohort included patients with relapsed tumors potentially dependent on sonic hedgehog (Shh) signaling 27; 33 patients were included, 24 of whom had a medulloblastoma. This evidence concerns the gene SHH and medulloblastoma.